Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
( https://imaging.iq.msu.edu/ ) and clinical imaging resources ( https://biomedicalimaging.msu.edu ). They will interact with our Precision Health Program (PHP; https://radiology.msu.edu/research
-
radiopharmaceutical technologies. Ideal candidate combines deep technical expertise with industry experience evaluating biomedical innovations within pharmaceutical, biotechnology, imaging, or venture
-
(American Registry of Radiologic Technologists) Clinical Ladder State- of -the- art- technology Join the Duke Health Nuclear Medicine Team! https://duke.is/nucmed General Description of the Job
-
throughout South Texas. Developing a Molecular Imaging, Theranostics, and Radiopharmaceutical Oncology Program, including expansion of diagnostic and therapeutic isotope capabilities and leadership in
-
Institute of Radiology’s clinical theranostics program provides personalized medical management through targeted radiopharmaceutical diagnosis and therapy. The selected candidate will work collaboratively
-
—clinical, research, education, and culture—within the division. Provide strategic vision for the growth of theranostics, molecular imaging, and radiopharmaceutical therapy programs across the IU Health
-
ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA - - DIPARTIMENTO DI FISICA E ASTRONOMIA | Bologna, Emilia-Romagna | Italy | 26 days ago
Description The candidate will develop an innovative ionizing radiation detector prototype based on perovskite thin films, capable of monitoring radiopharmaceutical activity in real time. This prototype
-
collaborative, multidisciplinary participation of nuclear medicine in the oncology practice at SCCA. Multiple diagnostic and therapy radiopharmaceutical clinical trials are also run or supported by the
-
participation of nuclear medicine in the oncology practice at SCCA. Multiple diagnostic and therapy radiopharmaceutical clinical trials are also run or supported by the Fred Hutch nuclear medicine service
-
radiopharmaceutical sciences and/or conducting biological assays (in vitro/in vivo) The research will be conducted at the Lyon Cancer Center (CRCL, UMR CNRS 5286, Inserm U1052, UCBL, CLB) and aims to characterize new